Vor is a biotech company dedicated to advancing science to change the course of disease.
Join Vor in tackling autoimmune disease at its root by advancing telitacicept, a first- and potentially best-in-class dual BAFF/APRIL inhibitor. The Vice President, Disease Area Leader-Neuromuscular Disease will lead late-stage clinical development in neuro-immunology portfolio, driving pivotal-stage execution and ensuring programs are positioned for regulatory approval and commercial readiness.
Vor is a biotech company dedicated to advancing science to change the course of disease.
Vor Bio